Biocartis Group NV (BCART.BR)

0.715 €

+0.01 (+0.70%)
Rating:
Recommendation:
-
Symbol BCART.BR
Price 0.715 €
Beta 1.376
Volume Avg. 0.22M
Market Cap 66.568M
Shares () -
52 Week Range 0.512-3.03
1y Target Est -
DCF Unlevered BCART.BR DCF ->
DCF Levered BCART.BR LDCF ->
ROE 406.90% Strong Buy
ROA -56.96% Strong Sell
Operating Margin -
Debt / Equity -270.80% Sell
P/E -
P/B -0.65
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Herman Verrelst
Healthcare
Diagnostics & Research
Brussels

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.